Testosterone replacement therapy market to grow by USD 439.67 million between 2022 and 2027; Growth driven by initiatives to increase awareness about hypogonadism - Technavio

NEW YORK, May 2, 2023 /PRNewswire/ -- The testosterone replacement therapy market size is forecast to increase by USD 439.67 million from 2022 to 2027, at a CAGR of 3.38%, according to the recent market study by Technavio. The growth of the market will be driven by the initiatives to increase awareness about hypogonadism among the population, rising chronic diseases, and the increasing aging population and postmenopausal women. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download The Sample Report

Vendor Analysis

The global testosterone replacement therapy market is fragmented, with many small-to-large-scale vendors. Key vendors hold significant shares in the market. Established vendors have strong financial abilities and technical expertise in offering safer and more effective products. The established vendors are deploying a significant share of their capital in product R&D and are focusing on adopting organic growth strategies such as product launches to bring considerable differentiation in their products and gain higher customer penetration. The small-scale vendors are competing with the established vendors by using low-price strategies and strengthening their local customer base. The market is likely to remain dominated by some of the prominent large-scale vendors that offer US FDA-approved and renowned testosterone replacement therapy drugs during the forecast period. Some of the key vendors covered in the report include:

• AbbVie Inc. - The company offers testosterone replacement therapy such as Androderm.
• Acerus Pharmaceuticals Corp. - The company offers testosterone replacement therapy such as Natesto.
• Alembic Pharmaceuticals Ltd. - The company offers testosterone replacement therapy such as gel with 20.25 mg and 1.25 gm actuation.
• Amneal Pharmaceuticals Inc. - The company offers testosterone replacement therapy such as CIII gel for topical use.
• Actiza Pharmaceutical Pvt. Ltd.
• Alvogen Iceland ehf
• Antares Pharma Inc.
• Bausch Health Co. Inc.
• Bayer AG
• Cipla Ltd.
• Eli Lilly and Co.
• Endo International Plc
• Ferring BV
• Halozyme Therapeutics Inc.
• Lupin Ltd.

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Analyse the data and grow your profit margin with Technavio - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get a holistic overview of the testosterone replacement therapy market to develop growth strategies. Download the Sample

Market Segmentation:

The market is segmented by distribution channel (hospitals, retail, and online), product (injectables, topicals, and others), and geography (North America, Europe, Asia, and Rest of World).

The market growth in the hospitals segment will be significant over the forecast period. Hospital pharmacies provide advice on drug dosages, interactions, and potential side effects, as well as monitor patient adherence to medication regimes. This helps in improving patient outcomes. Hospital pharmacies also assist in clinical trials to test the safety and efficacy of new drugs. As a result of these factors, the hospital pharmacy segment is expected to dominate the market growth during the forecast period.

North America will account for 57% of the market growth during the forecast period. The growth of the regional market is driven by the strong presence of key vendors and the easy availability of new and improved products. The increasing cases of hypogonadism and rising awareness about the treatment of testosterone deficiency and erectile dysfunction are other factors driving the growth of the testosterone replacement therapy market in North America.

Market Dynamics:

Key DRIVERS:

• Initiatives to increase awareness about hypogonadism among the population
• The rise in chronic diseases
• Increasing aging population and postmenopausal women

Many organizations are working on increasing patient awareness regarding hypogonadism and available treatment options. For instance, Endocrine Society has undertaken various initiatives to increase awareness about hypogonadism among medical professionals. It has released clinical practice guidelines on testosterone therapy, which helps in the safer delivery and reduction of adverse events. Similarly, organizations such as the Testicular Cancer Awareness Foundation, Endocrine Awareness Center for health, and the AUA are educating the population about the diagnosis and treatment of hypogonadism. Such awareness programs have led many patients to proactively approach fertility care centers and medical practitioners to undertake testosterone replacement therapy. All these factors are driving the growth of the market.

Major Trends:

• Rise in novel therapeutic approaches
• Patient assistance programs
• Growing new developments in the market

The market has witnessed a rise in the number of novel therapies to treat testosterone deficiency. Vendors in the market are increasing their R&D efforts to develop alternative treatment options that can ensure safe use during testosterone replacement therapies. The growing focus of vendors toward such therapeutic approaches is expected to contribute to the launch of new drugs. For instance, at the Endocrine Society's annual meeting, Dr. Fahim Ebrahimi presented the results of a recent study that analyzed the therapeutic effects of Anakinra on testosterone levels. According to the study, testosterone levels rose by 11% in the treatment group. Such developments are expected to foster the growth of the market during the forecast period.

Key Challenges:

• Availability of generics
• Adverse effects of testosterone replacement therapy
• Stringent regulations by the US FDA on the use of testosterone therapies

The number of generic drugs available for the treatment of testosterone deficiency is increasing in the market. For instance, the generic version of AndroGel produced by Lupin Pharmaceuticals, known as the testosterone gel, 1.62%, is approved by the FDA. Many such generic versions of popular drugs are entering the market. In addition, the low cost of generics is another major factor reducing the growth of the market.

Subscribe to our Basic Plan billed annually at USD 5000. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this testosterone replacement therapy market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the testosterone replacement therapy market between 2023 and 2027
• Precise estimation of the size of the testosterone replacement therapy market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the testosterone replacement therapy market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of testosterone replacement therapy market vendors

Related Reports:

The protein therapeutics market size is estimated to grow at a CAGR of 9.14% between 2022 and 2027. The market size is forecast to increase by USD 153.56 billion. The market is segmented by product (mABs, human insulin, erythropoietin, clotting factors, and others), application (metabolic disorders, immunologic disorders, hematological disorders, cancer, and genetic disorders), and geography (North America, Europe, Asia, and Rest of World (ROW)).

The cardiovascular therapeutics market size is estimated to grow at a CAGR of 7.32% between 2022 and 2027. The cardiovascular therapeutics market size is forecast to increase by USD 37.77 billion. The market is segmented by type (antithrombotic drugs, hypolipidemic drugs, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (Asia, North America, Europe, and Rest of World).

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global Testosterone Replacement Therapy Market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global Testosterone Replacement Therapy Market 2017 - 2021 ($ million)

• 4.2 Distribution Channel Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.3 Product Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 6.2 Comparison by Distribution Channel 
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel

• 6.3 Hospitals - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)

• 6.4 Retail - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Retail - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Retail - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Retail - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Retail - Year-over-year growth 2022-2027 (%)

• 6.5 Online - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Distribution Channel 
• Exhibit 46: Market opportunity by Distribution Channel ($ million)
• Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Product

• 7.1 Market segments
• Exhibit 48: Chart on Product - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Product - Market share 2022-2027 (%)

• 7.2 Comparison by Product 
• Exhibit 50: Chart on Comparison by Product
• Exhibit 51: Data Table on Comparison by Product

• 7.3 Injectables - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Injectables - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Injectables - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Injectables - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Injectables - Year-over-year growth 2022-2027 (%)

• 7.4 Topicals - Market size and forecast 2022-2027 
• Exhibit 56: Chart on Topicals - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Topicals - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Topicals - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Topicals - Year-over-year growth 2022-2027 (%)

• 7.5 Others - Market size and forecast 2022-2027 
• Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Product 
• Exhibit 64: Market opportunity by Product ($ million)
• Exhibit 65: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 67: Chart on Market share by geography 2022-2027 (%)
• Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Canada - Market size and forecast 2022-2027 
• Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027 
• Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 UK - Market size and forecast 2022-2027 
• Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027 
• Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 107: Market opportunity by geography ($ million)
• Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 109: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 114: Matrix on vendor position and classification

• 12.3 AbbVie Inc.
• Exhibit 115: AbbVie Inc. - Overview
• Exhibit 116: AbbVie Inc. - Product / Service
• Exhibit 117: AbbVie Inc. - Key news
• Exhibit 118: AbbVie Inc. - Key offerings

• 12.4 Acerus Pharmaceuticals Corp. 
• Exhibit 119: Acerus Pharmaceuticals Corp. - Overview
• Exhibit 120: Acerus Pharmaceuticals Corp. - Product / Service
• Exhibit 121: Acerus Pharmaceuticals Corp. - Key offerings

• 12.5 Acrux Ltd.
• Exhibit 122: Acrux Ltd. - Overview
• Exhibit 123: Acrux Ltd. - Product / Service
• Exhibit 124: Acrux Ltd. - Key offerings

• 12.6 Alembic Pharmaceuticals Ltd. 
• Exhibit 125: Alembic Pharmaceuticals Ltd. - Overview
• Exhibit 126: Alembic Pharmaceuticals Ltd. - Product / Service
• Exhibit 127: Alembic Pharmaceuticals Ltd. - Key offerings

• 12.7 Amneal Pharmaceuticals Inc. 
• Exhibit 128: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 129: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 130: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 131: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 132: Amneal Pharmaceuticals Inc. - Segment focus

• 12.8 Antares Pharma Inc.
• Exhibit 133: Antares Pharma Inc. - Overview
• Exhibit 134: Antares Pharma Inc. - Product / Service
• Exhibit 135: Antares Pharma Inc. - Key offerings

• 12.9 Bausch Health Co. Inc. 
• Exhibit 136: Bausch Health Co. Inc. - Overview
• Exhibit 137: Bausch Health Co. Inc. - Business segments
• Exhibit 138: Bausch Health Co. Inc. - Key news
• Exhibit 139: Bausch Health Co. Inc. - Key offerings
• Exhibit 140: Bausch Health Co. Inc. - Segment focus

• 12.10 Bayer AG
• Exhibit 141: Bayer AG - Overview
• Exhibit 142: Bayer AG - Business segments
• Exhibit 143: Bayer AG - Key news
• Exhibit 144: Bayer AG - Key offerings
• Exhibit 145: Bayer AG - Segment focus

• 12.11 Cipla Ltd.
• Exhibit 146: Cipla Ltd. - Overview
• Exhibit 147: Cipla Ltd. - Business segments
• Exhibit 148: Cipla Ltd. - Key news
• Exhibit 149: Cipla Ltd. - Key offerings
• Exhibit 150: Cipla Ltd. - Segment focus

• 12.12 Endo International Plc 
• Exhibit 151: Endo International Plc - Overview
• Exhibit 152: Endo International Plc - Business segments
• Exhibit 153: Endo International Plc - Key news
• Exhibit 154: Endo International Plc - Key offerings
• Exhibit 155: Endo International Plc - Segment focus

• 12.13 Ferring BV
• Exhibit 156: Ferring BV - Overview
• Exhibit 157: Ferring BV - Product / Service
• Exhibit 158: Ferring BV - Key offerings

• 12.14 Halozyme Therapeutics Inc. 
• Exhibit 159: Halozyme Therapeutics Inc. - Overview
• Exhibit 160: Halozyme Therapeutics Inc. - Product / Service
• Exhibit 161: Halozyme Therapeutics Inc. - Key offerings

• 12.15 Pfizer Inc.
• Exhibit 162: Pfizer Inc. - Overview
• Exhibit 163: Pfizer Inc. - Product / Service
• Exhibit 164: Pfizer Inc. - Key news
• Exhibit 165: Pfizer Inc. - Key offerings

• 12.16 Sawai Pharmaceutical Co. Ltd. 
• Exhibit 166: Sawai Pharmaceutical Co. Ltd. - Overview
• Exhibit 167: Sawai Pharmaceutical Co. Ltd. - Business segments
• Exhibit 168: Sawai Pharmaceutical Co. Ltd. - Key offerings
• Exhibit 169: Sawai Pharmaceutical Co. Ltd. - Segment focus

• 12.17 Teva Pharmaceutical Industries Ltd. 
• Exhibit 170: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 171: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 172: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 175: Inclusions checklist
• Exhibit 176: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 177: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 178: Research methodology
• Exhibit 179: Validation techniques employed for market sizing
• Exhibit 180: Information sources

• 13.5 List of abbreviations 
• Exhibit 181: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio